^
Association details:
Biomarker:CEP290 mutation
Cancer:Multiple Myeloma
Drug:Xpovio (selinexor) (XPO1 inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: D – Preclinical
Source:
Title:

1061 - Characterization of synergistic selinexor combinations with dexamethasone, pomalidomide, elotuzumab, and daratumumab in primary MM cells

Published date:
03/10/2021
Excerpt:
WES also identified mutations associated with SELI sensitivity. Mutation of BCL7A, a protein involved in chromatin remodeling, was associated with sensitivity, and mutation of CEP290, which encodes a microtubule binding protein, was associated with resistance (p<0.05)....We established a platform to perform parallel RNA/exome sequencing and ex vivo drug sensitivity assessment on CD138+ cells from MM patient bone marrow aspirates.